Neuroendovascular Coil - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The neuroendovascular coil market size is projected to expand from USD 1.07 billion in 2025 and USD 1.14 billion in 2026 to USD 1.54 billion by 2031, registering a CAGR of 6.28% between 2026 and 2031. This report is segmented by Product Type (Bare Platinum, Hydrogel-Coated, Bioactive/Complex Coils), Application (Aneurysm Embolization, AVM, AVF, Stroke Intervention, Other), Detachment Mechanism (Electrolytic, Mechanical, Hydraulic, Thermal/Electrothermal), End User (Hospitals, Specialty Centers, and More), and Geography (North America, Europe, Asia-Pacific, and More). Market Forecasts in Value (USD).

Global Neuroendovascular Coil Market Trends and Insights

Rising Incidence of Intracranial Aneurysms and Stroke

The wider detection of unruptured intracranial aneurysms is changing a procedure category that was historically centered on urgent treatment after rupture. A 2025 systematic review and meta-analysis covering 304,848 subjects estimated global prevalence at 5.4%, with a 95% confidence interval of 4.2% to 6.8%. Female sex had an odds ratio of 1.722, hypertension had an odds ratio of 1.579, and smoking had an odds ratio of 2.266 in the review, which identifies a population with several overlapping risk factors. Magnetic resonance angiography screening in Japan and South Korea is identifying asymptomatic aneurysms earlier, before an emergency presentation, which determines the treatment route. Earlier diagnosis gives clinical teams more time to consider anatomy, treatment durability, procedural planning, and the characteristics of available coil platforms. The neuroendovascular coil market can therefore shift from emergency-led bare platinum use toward differentiated devices used in planned elective procedures, especially when patients enter a defined referral pathway before symptoms require urgent intervention, and clinicians can evaluate device options with greater procedural flexibility.

Preference for Minimally Invasive Aneurysm Treatment

Endovascular treatment remains central to care for many patients with ruptured intracranial aneurysms, particularly when a less invasive path is clinically suitable. A 2025 analysis reported a 75% higher hierarchical-outcome win ratio for endovascular coiling than surgical clipping across mortality, functional outcome, major complications, and intensive care unit stay. This evidence supports an endovascular-first approach in suitable cases, although treatment selection continues to depend on clinical presentation and aneurysm anatomy. It also reinforces demand for coils that address a range of aneurysm shapes and work with the catheter systems used in established services. Hospitals can maintain familiarity through procedural training, which supports consistent use of endovascular techniques across their neurovascular teams. The neuroendovascular coil market benefits when clinicians retain the ability to use less invasive treatment across a broader set of patients, because this can support treatment planning that considers both immediate clinical needs and the resources available within established neurovascular services.

High Procedure Costs and Specialist Workforce Shortages

Neurointerventional aneurysm treatment requires substantial capital investment and highly specialized clinical staffing, which can restrict adoption in lower-resource settings. Biplane fluoroscopy suites, interventional neuroradiology teams, and sustained monitoring capacity are core requirements that many secondary hospitals cannot easily finance or maintain. The American Society of Neuroradiology noted workforce shortages in rural areas in its comments on the 2026 Medicare physician fee schedule. Lower specialist density limits the procedures that a region can perform and makes it harder for local facilities to maintain a consistent service. It also limits the inventory levels that hospitals can justify for advanced coil platforms, especially where case volumes are uncertain. The neuroendovascular coil market consequently remains concentrated in urban hospitals and other high-volume centers with the staff, equipment, and monitoring resources required for care, leaving many smaller facilities dependent on referral pathways when patients require complex neurointerventional treatment.

Other drivers and restraints analyzed in the detailed report include:

• Aging Population and Neurovascular Risk-Factor Burden
• Expansion of Neurointerventional Infrastructure and Reimbursement
• Retreatment Risk From Recanalization and Coil Compaction

Segment Analysis

Bare platinum coils accounted for 58.31% of the neuroendovascular coil market size in 2025, supported by long clinical use and broad procedural familiarity. Hospitals use them across a wide range of aneurysm sizes and shapes because they work with many microcatheters and detachment systems. Their established role helps clinicians use a consistent approach when patient anatomy does not require a specialized device. Price remains important in routine procedures, particularly where hospitals must control the cost of disposable supplies. Hydrogel-coated coils are forecast to grow at an 8.65% CAGR through 2031, reflecting a different value proposition for higher-risk anatomy.

The neuroendovascular coil market size for hydrogel-coated coils is supported by the material’s ability to expand after blood contact and occupy more of the aneurysm sac. An updated meta-analysis of 6 randomized controlled trials found a more favorable 1-year occlusion trajectory for hydrogel-coated coils than bare platinum coils. The findings included greater thrombosis and less progression to body filling, both of which matter when clinicians assess durability. Bioactive and complex coils also hold a smaller but strategically important position because their coatings aim to support neoendothelialization. A 2025 in-vitro study reported earlier and greater endothelial cell proliferation on hydrocoils than on bare platinum coils. Coated devices are most relevant for wide-neck, complex, and previously treated aneurysms, while bare platinum products remain suitable for many simpler cases.

Intracranial aneurysm embolization represented 68.24% of the neuroendovascular coil market size in 2025, making it the main application for these devices. The indication has a large procedure base across neurointerventional services because coiling is a core treatment option for suitable aneurysms. It requires products in different sizes, shapes, and detachment formats to address variation in lesion anatomy. The clinical evidence base also supports the sustained role of endovascular treatment for ruptured aneurysms. A 2025 tertiary-center study reported a 75% higher hierarchical-outcome win ratio for coiling than for surgical clipping across mortality, functional outcome, major complications, and intensive care unit stay.

Stroke intervention is forecast to grow at a 7.42% CAGR through 2031 as comprehensive stroke networks expand access to time-sensitive neurovascular care. Coils are relevant in selected hemorrhagic stroke procedures, where precise placement and controlled deployment are needed. This use broadens the clinical role of suppliers beyond the main aneurysm indication. Arteriovenous malformation procedures can use coils before radiosurgery to reduce lesion volume. Arteriovenous fistula embolization is a smaller but technically demanding application where placement precision is particularly important. The neuroendovascular coil market benefits from several applications because diversified portfolios are less exposed to a reimbursement change in one procedure category.

Complete Report Scope:

• By Product Type
  • Bare Platinum Coils
  • Hydrogel-Coated Coils
  • Bioactive / Complex Coils
• By Application
  • Intracranial Aneurysm Embolization
  • Arteriovenous Malformation Embolization
  • Arteriovenous Fistula Embolization
  • Stroke Intervention
  • Other Applications
• By Detachment Mechanism
  • Electrolytic Detachable Coils
  • Mechanical Detachable Coils
  • Hydraulic / Hydrostatic
  • Thermal / Electrothermal
• By End User
  • Hospitals
  • Specialty Neurology Centers
  • Ambulatory Surgical Centers
  • Other End Users
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 36.61% of the neuroendovascular coil market share in 2025, supported by established reimbursement and high procedure volumes at academic medical institutions. The region has a dense network of comprehensive stroke centers and advanced neurointerventional services, especially in the United States. CPT codes 61624 and 61626 remain important to payment for cerebral embolization procedures in the United States. The Society of NeuroInterventional Surgery addressed payment protection for these codes in its 2026 advocacy work. U.S. regulatory clearance is also an important route for novel coil systems, with FDA records documenting relevant clearances from 2024 to 2026. Canada and Mexico add to regional demand, although specialist availability and advanced infrastructure remain concentrated in primary urban centers. Hence, the region’s procedures and purchasing power continue to be led by well-equipped hospitals that can maintain comprehensive neurovascular teams and standardized treatment pathways.

Europe is the second-largest geographic market in the neuroendovascular coil market, led by Germany, the United Kingdom, France, Italy, and Spain. The region has established neurointerventional training pathways, and coil embolization is integrated into routine aneurysm and stroke care in many national health systems. European Union medical device regulation requires extensive technical documentation and biocompatibility evidence for new coil designs. These requirements can extend the launch process, but they also limit the entry of products that cannot meet the required standards. WallabyPhenox reported a limited European release of the Avenir Pico coil after CE Mark approval in November 2025. Price controls, formal health technology assessments, and evidence-focused hospital procurement also shape the neuroendovascular coil market across Europe, creating a setting in which clinical validation, regulatory documentation, and the ability to meet institutional purchasing requirements are all important to sustained adoption.

Asia-Pacific is forecast to grow at an 8.25% CAGR through 2031, which is the fastest regional rate in the neuroendovascular coil market. East Asia combines a substantial neurovascular disease burden with expanding capacity for specialist treatment. In April 2026, the Japan Neurosurgical Society published an advisory on stent-assisted coil embolization for acute ruptured aneurysms. India is increasing access through digital subtraction angiography investment in private hospital networks, while South Korea has a mature and growing neurointerventional ecosystem. Australia maintains high procedural standards aligned with international clinical guidelines, and Brazil is expanding capacity through academic stroke centers and private hospital investment. Gulf Cooperation Council countries are building tertiary neurovascular facilities, creating new treatment sites across the Middle East and Africa. However, the broader region still faces uneven access to specialist staff, advanced imaging, and the clinical support needed for regular aneurysm embolization services.

List of Companies Covered in this Report:

• Acandis
• Asahi Intecc
• BALT Group
• Boston Scientific
• Cook Group
• Johnson & Johnson
• Kaneka
• Lepu Medical Technology (Beijing) Co., Ltd.
• Medtronic
• MicroPort
• Penumbra
• Phenox
• Rapid Medical Ltd.
• Shape Memory Medical
• Stryker
• Terumo
• Wallaby Medical
• Zylox-Tonbridge Medical Technology Co., Ltd.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support